ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 23 October 2026 APPENDIX 4C: QUARTER ENDED 30 SEPTEMBER 2026 Highlights for the quarter: • Reached clinical readiness, with the first two batches successfully manufactured and released for patient use during September 2026. •...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 13 pages · English
Summary by 6ix AI
Financially, Arovella reported a cash balance at the end of the quarter and highlighted its focus on advancing both its blood cancer and solid tumor programs. The report outlines key milestones and expectations for the upcoming quarter, including the initiation of patient dosing in clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Arovella receives R&D tax rebate of $4.03 million
- Second Clinical Batch Released for Immediate Patient Use
- Cell and Gene Innovation Spotlight Presentation
- Notice of Annual General Meeting/Proxy Form
- The path to first patient dosing
Later from Arovella Therapeutics
- First Patient Dosed with ALA-101
- Complete tumour clearance in gastric cancer animal study
- Arovella Appoints CEO
- 2026 AGM Presentation
- Correction to previous CEO appointment announcement
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics